120
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Future Landscape of Endothelial Cells Research in Psoriasis: Bibliometric Analysis and Literature Review

, , , , ORCID Icon &
Pages 3107-3120 | Received 11 Aug 2023, Accepted 24 Oct 2023, Published online: 30 Oct 2023

References

  • Sorokin AV, Kotani K, Elnabawi YA, et al. Association between oxidation-modified lipoproteins and coronary plaque in psoriasis. Circ Res. 2018;123(11):1244–1254. doi:10.1161/CIRCRESAHA.118.313608
  • Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–658. doi:10.1001/jamadermatol.2014.3593
  • Kimball AB, Guérin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25(2):157–163. doi:10.1111/j.1468-3083.2010.03730.x
  • Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7(10):803–815. doi:10.1038/nri2171
  • Chiang CC, Cheng WJ, Korinek M, Lin CY, Hwang TL. Neutrophils in psoriasis. Front Immunol. 2019;10(2376). doi:10.3389/fimmu.2019.02376
  • Matsushita Y, Shimada Y, Kawara S, Takehara K, Sato S. Autoantibodies directed against the protease inhibitor calpastatin in psoriasis. Clin Exp Immunol. 2005;139(2):355–362. doi:10.1111/j.1365-2249.2005.02701.x
  • Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057–1069. doi:10.7150/ijbs.7502
  • Williams JW, Huang LH, Randolph GJ. Cytokine circuits in cardiovascular disease. Immunity. 2019;50(4):941–954.
  • Wang W, Wang H. Astilbin reduces ROS accumulation and VEGF expression through Nrf2 in psoriasis-like skin disease. Biol Res. 2019;52(1):49.
  • Xian D, Song J, Yang L, Xiong X, Lai R, Zhong J. Emerging roles of redox-mediated angiogenesis and oxidative stress in dermatoses. Oxid Med Cell Longev. 2019;2019(2304018):1–14. doi:10.1155/2019/2304018
  • Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. doi:10.1056/NEJMra0804595
  • Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–873. doi:10.1038/nature05663
  • Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003;102(1):161–168. doi:10.1182/blood-2002-12-3793
  • Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol. 2009;90(3):232–248. doi:10.1111/j.1365-2613.2009.00669.x
  • Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180(3):1141–1146. doi:10.1084/jem.180.3.1141
  • Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
  • Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol. 2004;122(1):209–215. doi:10.1046/j.0022-202X.2003.22107.x
  • Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–1912. doi:10.1056/NEJMra041320
  • Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi:10.1001/jama.296.14.1735
  • Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648–651. doi:10.1038/nature05505
  • Griffiths CE, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol. 1989;20(4):617–629. doi:10.1016/S0190-9622(89)70073-6
  • Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature. 1991;349(6312):796–799. doi:10.1038/349796a0
  • Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol. 1999;141(6):1054–1060. doi:10.1046/j.1365-2133.1999.03205.x
  • Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.
  • Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–1006. doi:10.1093/eurheartj/ehp567
  • He Y, Kim J, Tacconi C, et al. Mediators of capillary-to-venule conversion in the chronic inflammatory skin disease psoriasis. J Invest Dermatol. 2022;142(12):3313–3326. doi:10.1016/j.jid.2022.05.1089
  • Young KZ, Plazyo O, Gudjonsson JE. Targeting immune cell trafficking and vascular endothelial cells in psoriasis. J Clin Invest. 2023;133(9). doi:10.1172/JCI169450
  • Lee HJ, Hong YJ, Kim M. Angiogenesis in chronic inflammatory skin disorders. Int J Mol Sci. 2021;22(21):12035.
  • Benhadou F, Glitzner E, Brisebarre A, et al. Epidermal autonomous VEGFA/Flt1/Nrp1 functions mediate psoriasis-like disease. Sci Adv. 2020;6(2):x5849. doi:10.1126/sciadv.aax5849
  • von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–1062. doi:10.1016/j.jid.2018.10.042
  • Weber B, Merola JF, Husni ME, Di Carli M, Berger JS, Garshick MS. Psoriasis and cardiovascular disease: novel mechanisms and evolving therapeutics. Curr Atheroscler Rep. 2021;23(11):67. doi:10.1007/s11883-021-00963-y
  • Lynch M, Ahern T, Sweeney CM, et al. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int J Dermatol. 2017;56(11):1103–1118. doi:10.1111/ijd.13699
  • Otto M, Dorn B, Grasmik T, et al. Apremilast effectively inhibits TNFα-induced vascular inflammation in human endothelial cells. J Eur Acad Dermatol Venereol. 2022;36(2):237–246. doi:10.1111/jdv.17769
  • Shao S, Fang H, Li Q, Wang G. Extracellular vesicles in inflammatory skin disorders: from pathophysiology to treatment. Theranostics. 2020;10(22):9937–9955. doi:10.7150/thno.45488
  • Elnabawi YA, Garshick MS, Tawil M, et al. CCL20 in psoriasis: a potential biomarker of disease severity, inflammation, and impaired vascular health. J Am Acad Dermatol. 2021;84(4):913–920. doi:10.1016/j.jaad.2020.10.094
  • Liu JH, Chen Y, Zhen Z, et al. Relation between endothelial progenitor cells and arterial stiffness in patients with psoriasis. J Dermatol. 2016;43(8):888–893. doi:10.1111/1346-8138.13235
  • Batycka-Baran A, Paprocka M, Krawczenko A, Kantor A, Duś D, Szepietowski JC. Reduced number of circulating endothelial progenitor cells (CD133+/KDR+) in patients with plaque psoriasis. Dermatology. 2012;225(1):88–92. doi:10.1159/000341534
  • Reynolds G, Vegh P, Fletcher J, et al. Developmental cell programs are co-opted in inflammatory skin disease. Science. 2021;371(6527). doi:10.1126/science.aba6500
  • Li Z, Wang M, Tan J, et al. Single-cell RNA sequencing depicts the local cell landscape in thyroid-associated ophthalmopathy. Cell Rep Med. 2022;3(8):100699. doi:10.1016/j.xcrm.2022.100699